Week in Review: Columbia China Building $150 Million Hospital in Jiaxing
August 26, 2017 at 04:05 AM EDT
- Columbia China , a JV formed by Seattle's Columbia Pacific and Temasek from Singapore , is building a $150 million 500-bed multi-specialty hospital in Jiaxing , Zhejiang Province; - Fosun Pharma may scale back its $1.3 billion, 86% acquisition of India 's Gland Pharma to a 74% transaction that will circumvent an expected rejection from India 's regulators; - Samsung Bioepis of South Korea announced a joint venture with Japan 's Takeda Pharma to develop novel biologic drugs, starting with a pancreatitis treatment; - HitGen of Chengdu and Houston will use its platform to discover drugs in a partnership with Aduro Biotech, a California immunocology company; - Zhejiang Hisun Pharma will provide scale-up services for a novel inhaled drug resistant TB treatment developed by Seattle 's Infectious Disease Research Institute; - Eone-Diagnomics Genome Center Co. of South Korea will form a JV with GPBio of China to expand Asian markets for their consumer and genetic analysis services; - GlaxoSmithKline China will partner with Ali Health to promote Cervarix, GSK's HPV/cervical cancer vaccine in China . Stock Symbols: (SHA: 600196; HK: 2196) (KS: 207940) (TYO: 4502) (NSDQ: ADRO) (SHA: 600267) (NYSE: GSK) Share this with colleagues: // //